Harrow Inc
Harrow Inc (HROW) Wheel Strategy
HROW wheel strategy scan found 40 cash-secured put setups on the previous trading day. Probability of expiring worthless is above 50%. Annualized returns reach up to 59.7%.
Read more
Running a HROW wheel strategy lets you generate consistent premium income on Harrow Inc while setting your own entry and exit prices on the underlying. Harrow Inc's wheel combines cash-secured puts and covered calls into a repeatable cycle: sell puts at strikes where you'd be happy to own HROW, and if assigned, sell calls at strikes where you'd be happy to sell. Use our scanner to find the best HROW wheel strategy setups in real time.
The wheel works best on liquid, high-quality names with stable fundamentals and active options markets — exactly the profile many large-cap leaders fit. The mechanics are simple: sell a cash-secured put on HROW, collect premium, and either keep the premium if it expires worthless or take assignment at a discount to current price. Once assigned, sell covered calls against the shares to keep collecting premium until they're called away. Choosing the right strikes, expirations, and IV environment is what separates a profitable HROW wheel from a losing one.
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.
Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
The difference between a wheel that compounds and one that bleeds comes down to strike selection, IV timing, and discipline on assignment. Our scanner handles the heavy lifting: it ranks every leg of the HROW wheel strategy by delta, premium yield, IV rank, and days to expiration, so you can deploy capital where the math works. Build your HROW wheel strategy on data, not gut feel — and let the options wheel do what it does best: pay you to wait.
| Oct 16, 2026 | 29.00 | $0.25 | $1.38 | -0.25 | 29 | 2% | 81.6% | 59.7% | 13 |
| Nov 20, 2026 | 32.00 | $1.15 | $3.03 | -0.39 | 64 | 2% | 53.7% | 53.9% | 0 |
| Nov 20, 2026 | 31.00 | $0.55 | $2.68 | -0.35 | 64 | 2% | 59.7% | 49.2% | 0 |
| Nov 20, 2026 | 30.00 | $0.65 | $2.43 | -0.31 | 64 | 2% | 65.6% | 46.1% | 0 |
| Dec 18, 2026 | 32.00 | $1.80 | $3.40 | -0.38 | 92 | 2% | 52.1% | 42.2% | 23 |
| Nov 20, 2026 | 29.00 | $0.45 | $2.13 | -0.27 | 64 | 2% | 71.4% | 41.8% | 0 |
| Jan 15, 2027 | 32.00 | $2.30 | $4.10 | -0.38 | 120 | 2% | 50.9% | 39.0% | 28 |
| Nov 20, 2026 | 28.00 | $0.10 | $1.90 | -0.24 | 64 | 2% | 76.8% | 38.7% | 0 |
| Oct 16, 2026 | 32.00 | $0.10 | $0.95 | -0.35 | 29 | 2% | 57.9% | 37.4% | 14 |
| Dec 18, 2026 | 31.00 | $1.30 | $2.85 | -0.34 | 92 | 2% | 57.1% | 36.5% | 2 |
As of September 18, 2026
Run the Wheel on HROW With Confidence
Find the best HROW wheel strategy setups across strikes and expirations, plan ahead with at-strike values, and keep your covered calls and puts on track.
Start your 14-day free trial→